Our Company Logo



The Scarlett Fund at Memorial Sloan Kettering Cancer Center (MSK) was created by Jennifer and Robert James to support

and raise awareness for pediatric cancer research in honor of their 8 year-old daughter, Scarlett James,

who was diagnosed in 2013 with T Cell Lymphoma.


Scarlett was diagnosed with T Cell Lymphoma, a rare form of pediatric cancer, at age 6. Aware of the sacrifices children and their families had made before them to make Scarlett's treatment possible, the James Family is inspired to help children that follow behind Scarlett with the hope that their treatment is less lengthy, less intense and less toxic. The money raised is being used to research novel targeted therapies which have great potential. Because these therapies target cancer cells, they reduce toxicity to healthy tissues and decrease long terms side effects. This is especially important for growing children.


Nearly 16,000 children and adolescents in the United States will be diagnosed with cancer this year. MSK is entrusted with many of these young lives, as we treat more children with cancer than any other institution in the world. Our families come here from all over the world—sometimes after exhausting options at other hospitals—to access the most effective and novel therapies. Even though the number of children diagnosed with cancer is growing each year, pediatric cancers are considered rare and receive only 4% of the US federal funds allocated to cancer research.

Gifts to The Scarlett Fund support a groundbreaking pediatric precision medicine initiative at MSK. Although there have been significant advances in the treatment of childhood cancers, the main treatment option is still chemotherapy, which can be harmful, not just to cancer cells, but also to a child’s healthy cells as well. This initiative focuses on identifying genetic mutations and developing targeted therapies for children with cancer.

As we enter a new era of precision medicine, it is vital that we continue to develop personalized treatments for children with cancer. In order to do this, we must also build the infrastructure needed to perform tumor sequencing and genetic testing for pediatric patients. Your support of The Scarlett Fund allows MSK to pursue these goals and bring new and more effective treatments to children with cancer across the world.